Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2022 - 2024)

NewAmsterdam Pharma's Total Non-Current Liabilities history spans 3 years, with the latest figure at $41.5 million for Q3 2024.

  • For Q3 2024, Total Non-Current Liabilities changed N/A year-over-year to $41.5 million; the TTM value through Sep 2024 reached $41.5 million, changed N/A, while the annual FY2023 figure was $50.9 million, 330.18% up from the prior year.
  • Total Non-Current Liabilities for Q3 2024 was $41.5 million at NewAmsterdam Pharma, down from $45.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $60.2 million in Q1 2024 and bottomed at $11.8 million in Q4 2022.
  • The 3-year median for Total Non-Current Liabilities is $45.9 million (2024), against an average of $42.1 million.
  • The largest YoY upside for Total Non-Current Liabilities was 330.18% in 2023 against a maximum downside of 330.18% in 2023.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $11.8 million in 2022, then skyrocketed by 330.18% to $50.9 million in 2023, then fell by 18.45% to $41.5 million in 2024.
  • Per Business Quant, the three most recent readings for NAMS's Total Non-Current Liabilities are $41.5 million (Q3 2024), $45.9 million (Q2 2024), and $60.2 million (Q1 2024).